COVID-19 Prevention and Management: HIV Coinfection, Outpatient Management, Hospitalization, and Post-COVID-19 Complications

Last Modified: Sep 15, 2022 @ 3:50 PM

Program Description

This course will be a half-day virtual update covering the latest clinical updates on COVID-19.

This course will include an overview of the clinical relationship between HIV and COVID-19, 2 case-based panel discussions on difficult cases in prevention, outpatient care, and inpatient care for COVID-19, including what drugs to use and when, and a discussion on post-COVID-19 complications, including our current understanding of the mechanisms of long-COVID-19.

Assessment of Needs

Rapid advances in HIV and COVID-19 requires the ongoing attention of practitioners involved in direct patient care. This course will address the implications of new information on strategies for the clinical management COVID-19 in different clinical settings. Information will be presented through a mix of didactic lectures, clinically relevant cases, and a roundtable discussion developed and led by an expert faculty of HIV/AIDS and COVID-19 clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be better able to:

• Describe the potential interaction between COVID-19 and HIV
• Describe current and investigational therapeutics for the prevention and treatment of acute COVID-19
• Describe the current best understanding of the long-term complications of COVID-19

Conflicts of Interest

In the interest of maintaining the independence of its continuing education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they or their spouses or partners have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA continuing education activity.

The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Registration

Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection or COVID-19 and:

• Provide comprehensive or specialty care for patients with HIV infection
• Provide outpatient or inpatient care for patients with COVID-19
• Are currently active in HIV or COVID-19 research

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 8 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.